Include in Biological Technology

FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD

ADHD symptom control demonstrated from the first time point measured (1.5 hours) through 13 hours postdose PHILADELPHIA, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced that the US Food and Drug Adminis...

Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio

Med Discovery SA, a specialized protein-based therapeutics oncology company, is proud to announce that they have extended their global partnership agreement with Laborium Biopharma, a subsidiary of Validapro BioSciences Inc. to encompass the cell culture process development and clinical manufactu...

Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial

SCHAUMBURG, Ill., Feb. 9 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefazolin for injection, USP, an essential antibiotic used to treat serious infections, in a 500mg single-dose vial. The 500mg s...

Sangui Bio Tech International Inc. Shareholders' Meeting Delayed to Include FY 2008 Report

WITTEN, Germany, September 17 /PRNewswire/ -- Sangui BioTech International, Inc., is currently preparing its financial statements for its 2008 financial year (ended June 30, 2008). The ensuing report on form 10KSB will be filed with the SEC and made public in due course. It will be included in...

Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)

ABBOTT PARK, Ill. and WILMINGTON, Del., Aug. 14 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) and AstraZeneca (NYSE: AZN ) announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR(R) (rosuvastatin calcium), a medication used along with diet to redu...

Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores

Study Published in the Journal of Clinical Oncology Proves Accurate Measurement of ER and PR Status Using Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) REDWOOD CITY, Calif., June 2 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) tod...

Spectral and Toray expand collaboration to include new geographic territories

TORONTO, May 5 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that it has expanded its relationship with Toray Medical Co. Ltd. for the marketing and sale of Spectral's Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxi...

Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees

- New Federal Rules Authorizing DNA Testing of Federal Arrestees Expected to Boost Law Enforcement's Ability to Combat Crime - - Complements Recent Moves by States to Expand their DNA Databases - PRINCETON, N.J., April 18 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH )...

UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGo's Platform

ST. JOSEPH, Mich., Jan. 8 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that UC Berkeley will expand the use of its MetaCore/MetaDrug Discovery Platform in their Computational Toxicology course, a required component f...

MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas

- Expands Staff to Continue Record of Investment Success - GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- MedImmune, the operationally independent worldwide biologics unit of AstraZeneca plc (LSE: AZN.L, NYSE: AZN), today announced that its highly successful venture capital fund, MedImmune V...

HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta

LEXINGTON, Mass., Dec. 19 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that its three-year contract covering its critical care portfolio with HealthTrust Purchasing Group, LP (HealthTrust), a leading group purchasing organization, has been extended to all Consorta, Inc. memb...

FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia

Study Data Demonstrated Improved Progression-free Survival with Campath CAMBRIDGE, Mass. and WAYNE, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) and Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY ) today announced that the U.S. Food and Drug Administration (FDA) h...

Thompson's HHS legacy will include efforts to combat disease in Africa

Pictured: Dan Vogel, Department of Health and Human Services; Tom Still, Wisconsin Technology Council; Tommy G. Thompson, Department of Health and Human Services and park warden at Arusha National Park near Mt. Kilimanjaro in Tanzania Arusha, Tanzania Even if former Wisconsin Gov. Tommy Tho...

Symposium will include venture capital "coaching"

Madison, Wis. - What do venture coaching, the "Elevator Pitch Olympics," and venture readiness workshops have in common? All will be components of the second annual Wisconsin Early Stage Symposium, which will be held on Monday and Tuesday, Oct. 30 and 31, at Monona Terrace Convention Center. ...

DHC 2007: Barriers to electronic data exchange include the law

Madison, Wis . - The state's mental health statues will have to be updated to accommodate electronic patient data exchange, according to Madison area health technologists. Patient data exchange was addressed in two sessions at Digital Healthcare Conference 2007 , including one that posed the q...

KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

...rities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning the operations, future results and prospects of the ...the forward-looking statements and related assumptions. Such factors include (but are not limited to) the following: (1) the ability to continue as a go...

Schering-Plough Shareholders Approve Merger With Merck

... "expect," "forecast," "project," "intend," "plan," "potential," "will," and other similar words and terms. In particular, forward-looking statements include statements about the timing and potential benefits of the proposed merger between Merck and Schering-Plough; Schering-Plough's and the combined compan...

Novavax Reports Second Quarter 2009 Financial Results

...y executives to support the future growth of the company. New appointments include Mr. John Trizzino as Senior Vice President, International and Governmental ...esults discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any pr...

Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

...s news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding expectations as to completion and timing of any public offering. These statements are subject to risks and u...

AutoImmune Inc. Reports 2009 Second Quarter Financial Results

...re forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they i...

GenVec Reports Second Quarter 2009 Financial Results

...ime. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating t o certain of our...

ThermoGenesis Provides Update on Fiscal 2009 Results

...ly $ 0.7 million. The non-cash charges primarily include $0.3 million in reserves for costs related to a tr...harges totaling approximately $0.9 million. These include approximately $0.2 million to support the releas... System and Res-Q. Key elements of this agreement include shared funding for clinical studies to demonstrate...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...l cohorts to explore the interferon-free regimen in treatment-experienced patients, both treatment failures and null-responder HCV patients, and would include twice-daily dosing of ITMN-191 and significantly higher total daily doses (600mg and 900mg twice daily) than those explored in the first four patient ...

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

...f Cell Stem Cell in an article titled "DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor Initiating Cell Frequency." The authors of the article include Dr. Michael Clarke of Stanford University, Dr. Hoey and Dr. Austin Gurney of OncoMed Pharmaceuticals, where OMP-21M18 was discovered and is being deve...

Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast

...d high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academi...he fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE((R)) DHPLC Systems, related consumables and assay kits, cytogenetics a...

China Sky One Medical, Inc. Appoints New Independent Director

..."seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the change of independent directors. Actual results could differ materially from the expectations refle...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...nt currently marketed Proprietary Medical Products include (i) our Quill(TM) SRS wound closure product line, ... a number of potential competitive benefits, which include a unique filter design that may reduce the potenti... financial results presented in this press release include non-GAAP measures that exclude certain items. Adju...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

...ated deficit (114,963,241) (113,857,261) Stockholders' equity 68,258,162 69,123,431 *does not include restricted cash This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A...

Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval

...rest receivable as of June 30, 2009. This does not include approximately $41.7 million, net of underwriting d...urities. Specifically, the risks and uncertainties include statements about our ability to continue to reduce...ent of OPAXIO, pixantrone, and brostallicin, which include risks associated with preclinical and clinical dev...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...point will be the change in the amount of kidney interstitial capillary GL-3 as measured in kidney biopsies using histology. Secondary endpoints will include safety and tolerability, kidney GL-3 as measured in urine, and an assessment of renal function (including glomerular filtration rate (GFR) and 24-hour...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

...eting in the acute care area. His responsibilities include sales, marketing and supply chain operations. ...re amounts for three and six month periods of 2008 include only the effect of the 2008 common stock issuance....liefs and expectations. Forward-looking statements include statements regarding: the company's belief that Ac...

AIAG and MichBio Form New Collaborative Partnership

...evelopment and harmonized business practices. AIAG membership has grown to include preeminent OEMs such as Caterpillar, Chrysler LLC, Daimler, Ford Motor Comp...ted to driving the growth of Michigan's life science industry. Its members include life sciences companies, academic and research institutions, bioscience ser...

GeoVax Labs, Inc. Provides Clinical Studies Update

...d Vanderbilt University, Nashville. The trial is still expected to include a total of 225 volunteers (150 vaccine recipients and 75 placebo recipients...s: 11 in North America and two in South America. Sites in the United States include Emory University, Atlanta; Harvard Medical School, Boston; Vanderbilt Unive...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... had approved a change to the prescribing information for VYVANSE, to include supplemental data that demonstrated significant ADHD symptom control ...ne 30, 2009 (2008: $0.9 million). Selling, general and administrative costs include amortization and impairment charges of intangible assets relating to intell...

BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing

...rmulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in ever...ducts that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform te...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...ve and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is curre...pectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. ...

Pharmacyclics, Inc. Rights Offering Oversubscribed

... for pursuant to notice of guaranteed delivery, which the Company expects to have completed on or before August 5, 2009. Participants in the offering include Federated Kaufmann Funds, Perceptive Advisors LLC, Quogue Capital LLC, Special Situations Life Sciences Fund and Suttonbrook Capital Management, among...

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

...ive Disease Week 2009 Conference focusing on patient risk factors believed to be predictive of CDI recurrence following treatment. These risk factors include albumin levels, white blood cell (WBC) count and temperature and strain types of CDI. The data showed that fidaxomicin overall demonstrated a lower re...

NxStage Reports Second Quarter 2009 Financial Results

...ents. Examples of these forward-looking statements include statements as to anticipated operating results, in... ==== ==== ==== ===== * Adjusting items include stock-based compensation, deferred revenue r... ==== ==== * Adjusting items include stock-based compensation, deferred revenue r...

Saint-Gobain Introduces Next Generation Silicone Tubing

...roducts. Other features that distinguish Sani-Tech(R) Ultra products include excellent flexibility, laser etching for lot traceability and non-yellowing...50 and 65 durometers and 91 different ID/OD combinations. Available options include bulk spool packaging and pre-delivery gamma irradiation. Custom sizes, leng...